Immuno-oncology Clinical Trials Market Progressing At A CAGR Of 13.6% From 2021 To 2028
![Image](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjDKS9kVQQ6odZF8ah5HY2BzOhYdsIX8E4kKxphFIwbtDpebBlMSmghON-tY1ubeuE93OgfTFu80pGOdVBnNFvC4CmSX5AThXL3EOT8cHK1wybEBB5DOBxS368oiER72AHJz5iMxXcuzmTa/s320/Immuno-oncology+Clinical+Trials+Market.png)
San Francisco, 12 July 2021: The Report Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Design (Interventional Trials, Observational Trials), By Indication, By Region, And Segment Forecasts, 2021 - 2028 The global immuno-oncology clinical trials market size is expected to reach USD 15.1 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 13.6% from 2021 to 2028. The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer. From 2014 to 2017, the number of new immuno-oncology studies increased from 250 to almost 600, with double-digit growth rates each year as drug classes diversified. Biomarker and checkpoint inhibitor studies were primarily responsible for this rapid growth. While the immuno-oncology market is maturing in some pharmacologi